Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

← catalyst calendar

NCT06162221 · readout ≤ 315 d

Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

616estimated

Sites

Countries

Australia, Austria, Czechia +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-01-18

actual

When the study began enrolling

Primary completion

Jun 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2028

estimated

The whole study's end, after follow-up

First posted

2023-12-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-30

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non-Small Cell Lung Cancer, NSCLC
KRAS, NRAS, HRAS-mutated NSCLC
KRAS G12C-mutated Solid Tumors, Lung Cancer
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
RAS G12D-mutated NSCLC

Interventions

Drug: RMC-6291
Drug: RMC-6236
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: RMC-9805

Primary outcomes

what the primary-completion date above is the date OF

Adverse events

measured Up to 5 years

Dose limiting toxicities

measured 21 days

Publications

PMID 40056080 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed